Gensight Biologics SA Stock
Price
Target price
€0.39
€0.39
2.660%
0.01
2.660%
-
09.05.24 / Stuttgart Stock Exchange
WKN: A2ANGZ / Name: Gensight / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Gensight Biologics SA Stock
There is an upward development for Gensight Biologics SA compared to yesterday, with an increase of €0.010 (2.660%).
For the coming years our community has positive and negative things to say abot the Gensight Biologics SA stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Gensight Biologics SA in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Gensight Biologics SA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Gensight Biologics SA | 2.660% | 0.805% | -1.830% | -42.052% | -15.237% | -95.818% | -78.809% |
| Protara Therapeutics Inc. | -1.400% | -2.920% | -15.287% | -6.338% | 60.241% | -89.698% | - |
| Celsion Corp. | 0.800% | 0.820% | -10.219% | 0.820% | 67.347% | -90.629% | - |
| CEL-SCI Corp. | 6.440% | 7.933% | -11.118% | -41.042% | -45.155% | -91.960% | - |
Comments
News
GenSight Biologics: Annual General Meeting on May 29, 2024
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Announces the Filing of its 2023 Universal Registration Document
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing